Literature DB >> 10364383

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.

R W Shafer1, P Hsu, A K Patick, C Craig, V Brendel.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) amino acid substitutions observed during antiretroviral drug therapy may be caused by drug selection, non-drug-related evolution, or sampling error introduced by the sequencing process. We analyzed HIV-1 sequences from 371 untreated patients and from 178 patients receiving a single protease inhibitor. Amino acid substitution patterns during treatment were compared with inferred substitution patterns arising evolutionarily without treatment. Our results suggest that most treatment-associated amino acid substitutions are caused by selective drug pressure, including substitutions not previously associated with drug resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364383      PMCID: PMC112692     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

1.  Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; T K Chuang; P Hsu; C B White; D A Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-01       Impact factor: 2.205

2.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Authors:  A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

3.  Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

Authors:  M J Kozal; N Shah; N Shen; R Yang; R Fucini; T C Merigan; D D Richman; D Morris; E Hubbell; M Chee; T R Gingeras
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

4.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

5.  Maintaining the integrity of human immunodeficiency virus sequence databases.

Authors:  G H Learn; B T Korber; B Foley; B H Hahn; S M Wolinsky; J I Mullins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.

Authors:  L Ruiz; M Nijhuis; C Boucher; T Puig; A Bonjoch; J Martínez-Picado; S Marfil; D de Jong; D Burger; A Arnó; M Balagué; B Clotet
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

7.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

Authors:  J H Condra; D J Holder; W A Schleif; O M Blahy; R M Danovich; L J Gabryelski; D J Graham; D Laird; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash; T Yang; J A Chodakewitz; P J Deutsch; R Y Leavitt; F E Massari; J W Mellors; K E Squires; R T Steigbigel; H Teppler; E A Emini
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Authors:  Y M Zhang; H Imamichi; T Imamichi; H C Lane; J Falloon; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env.

Authors:  M E Quiñones-Mateu; A Holguín; J Dopazo; I Nájera; E Domingo
Journal:  AIDS Res Hum Retroviruses       Date:  1996-08-10       Impact factor: 2.205

10.  The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Authors:  J M Schapiro; M A Winters; F Stewart; B Efron; J Norris; M J Kozal; T C Merigan
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

View more
  25 in total

1.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

3.  Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.

Authors:  Xianfeng Chen; Irene T Weber; Robert W Harrison
Journal:  J Mol Model       Date:  2004-09-28       Impact factor: 1.810

4.  Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers.

Authors:  Ricardo A Broglia; Guido Tiana; Ludovico Sutto; Davide Provasi; Fabio Simona
Journal:  Protein Sci       Date:  2005-10       Impact factor: 6.725

5.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

6.  Insight into the folding inhibition of the HIV-1 protease by a small peptide.

Authors:  Massimiliano Bonomi; Francesco L Gervasio; Guido Tiana; Davide Provasi; Ricardo A Broglia; Michele Parrinello
Journal:  Biophys J       Date:  2007-06-15       Impact factor: 4.033

7.  Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.

Authors:  Weerawat Manosuthi; David M Butler; Josué Pérez-Santiago; Art Fy Poon; Satish K Pillai; Sanjay R Mehta; Mary E Pacold; Douglas D Richman; Sergei Kosakovsky Pond; Davey M Smith
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

8.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

Review 9.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

10.  Multiple routes and milestones in the folding of HIV-1 protease monomer.

Authors:  Massimiliano Bonomi; Alessandro Barducci; Francesco L Gervasio; Michele Parrinello
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.